GR-1017

N/A

Report date: 2025/03/24 16:34:42
First In Class

Base Information

Drug NameGR-1017
Drug Alias NameBHV-1530GR-1017GQ-1011AMB-302
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > TopoIx payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsDNA topoisomerase I inhibitors
TargetsFibroblast growth factor receptor 3DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursCarcinoma, Transitional Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGeneQuantum Healthcare (Suzhou) Co LtdAimed Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiohaven LtdBiohaven Therapeutics LtdAimed Bio Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Transitional Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A